Screener
Ingevity NGVT R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by Ingevity in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Ingevity’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:26 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001653477-26-000035
| In millions, except per share data | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Cost of sales | 141.6 | 136.0 |
| Gross profit | 116.4 | 111.9 |
| Selling, general, and administrative expenses | 40.7 | 41.9 |
| Research and technical expenses | 6.7 | 7.0 |
| Restructuring and other (income) charges, net | 0.5 | 1.9 |
| Other (income) expense, net | 22.4 | 4.1 |
| Interest expense, net | 15.9 | 19.4 |
| Income (loss) from continuing operations before income taxes | 30.2 | 37.6 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ingevity's R&D?
- Ingevity (NGVT) reported R&D of $6.7M in Q1 2026.
- How has Ingevity's R&D changed year-over-year?
- Ingevity's R&D decreased by 4.3% year-over-year, from $7M to $6.7M.
- What is the long-term trend for Ingevity's R&D?
- Over 4 years (2021 to 2025), Ingevity's R&D has grown at a 2.6% compound annual growth rate (CAGR), from $26.3M to $29.2M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Ingevity's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude